ZymoGenetics, Inc. CEO Doug Williams Exits the Stage, Mulls Next Free Agent Move

Xconomy -- Doug Williams, one of the few nationally prominent biotechnology executives in Seattle, has officially left his job as ZymoGenetics CEO now that the company’s $885 million takeover by Bristol-Myers Squibb has been completed, Xconomy has learned.

MORE ON THIS TOPIC